药物更新：最近的药物批准，2025年冬季版。

IF 0.6 Q4 NURSING

NURSE PRACTITIONER Pub Date : 2025-02-01 Epub Date: 2025-01-23 DOI:10.1097/01.NPR.0000000000000271

Adriane B Marino, Jenna D Theroux, Evan S Drake, James Layton Anderson, Destiny S Self

{"title":"药物更新：最近的药物批准，2025年冬季版。","authors":"Adriane B Marino, Jenna D Theroux, Evan S Drake, James Layton Anderson, Destiny S Self","doi":"10.1097/01.NPR.0000000000000271","DOIUrl":null,"url":null,"abstract":"Abstract: In the first half of 2024, the US FDA approved several new drugs that have relevance for those practicing in primary care. This article, the winter 2025 edition of the journal's biannual Drug Update, highlights the following new medications: sotatercept-csrk (Winrevair), aprocitentan (Tryvio), resmetirom (Rezdiffra), berdazimer (Zelsuvmi), ceftobiprole medocaril sodium (Zevtera), sofpironium (Sofdra), and ensifentrine (Ohtuvayre).","PeriodicalId":51812,"journal":{"name":"NURSE PRACTITIONER","volume":"50 2","pages":"27-40"},"PeriodicalIF":0.6000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Drug Update: Recent drug approvals, winter 2025 edition.\",\"authors\":\"Adriane B Marino, Jenna D Theroux, Evan S Drake, James Layton Anderson, Destiny S Self\",\"doi\":\"10.1097/01.NPR.0000000000000271\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: In the first half of 2024, the US FDA approved several new drugs that have relevance for those practicing in primary care. This article, the winter 2025 edition of the journal's biannual Drug Update, highlights the following new medications: sotatercept-csrk (Winrevair), aprocitentan (Tryvio), resmetirom (Rezdiffra), berdazimer (Zelsuvmi), ceftobiprole medocaril sodium (Zevtera), sofpironium (Sofdra), and ensifentrine (Ohtuvayre).\",\"PeriodicalId\":51812,\"journal\":{\"name\":\"NURSE PRACTITIONER\",\"volume\":\"50 2\",\"pages\":\"27-40\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NURSE PRACTITIONER\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.NPR.0000000000000271\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"NURSING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NURSE PRACTITIONER","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.NPR.0000000000000271","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"NURSING","Score":null,"Total":0}

引用次数: 0

摘要

摘要：2024年上半年，美国FDA批准了几种与初级保健相关的新药。这篇文章是该杂志每年两次的药物更新的2025年冬季版，重点介绍了以下新药：sotaterept -csrk （Winrevair）、aprocitentan （Tryvio）、resmetirom （Rezdiffra）、berdazimer （Zelsuvmi）、ceftobiprole medocaril sodium （Zevtera）、sofpironium （Sofdra）和ensifentrine （Ohtuvayre）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Drug Update: Recent drug approvals, winter 2025 edition.

Abstract: In the first half of 2024, the US FDA approved several new drugs that have relevance for those practicing in primary care. This article, the winter 2025 edition of the journal's biannual Drug Update, highlights the following new medications: sotatercept-csrk (Winrevair), aprocitentan (Tryvio), resmetirom (Rezdiffra), berdazimer (Zelsuvmi), ceftobiprole medocaril sodium (Zevtera), sofpironium (Sofdra), and ensifentrine (Ohtuvayre).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

NURSE PRACTITIONER NURSING-

CiteScore

0.90

自引率

0.00%

发文量

183

期刊介绍： With a circulation of 20,000, The Nurse Practitioner is the leading monthly source for clinical, practical, cutting-edge information for advanced practice nurses and other primary care clinicians. Each issue presents peer-reviewed articles that range from clinical topics and research to political and practice issues. In addition, The Nurse Practitioner provides regular features, columns, continuing education, staff development education, and more.